Literature DB >> 3934270

High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61.

J W Lowenthal, P Corthésy, C Tougne, R Lees, H R MacDonald, M Nabholz.   

Abstract

In this report we characterize two classes of interleukin 2 (IL 2) binding sites on the basis of their differential IL 2 dissociation rate and of their reactivity with PC61, a monoclonal anti-IL 2 receptor (IL 2-R) antibody. PC61 inhibited the binding of IL 2 to both classes of receptor, but IL 2 did not inhibit the binding of PC61. This indicates that PC61 recognizes a determinant that is distal to the actual IL 2 binding site of the receptor. Dissociation experiments showed that the addition of excess unlabeled IL 2 resulted in a biphasic release of radiolabeled IL 2; 80 to 90% was dissociated rapidly (dissociation half-time, t1/2 of 60 sec) and the remainder more slowly (t1/2 60 to 90 min). The proportion of high and low affinity IL 2-R, as well as the relative difference in dissociation rates fit very well with the estimates derived previously from Scatchard plot analysis of equilibrium IL 2 binding. The addition of PC61 caused an accelerated dissociation of IL 2 from both high and low affinity IL 2-R (t1/2 of 16 and 120 sec respectively).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934270

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  An IL-4-independent and CD25-mediated function of c-maf in promoting the production of Th2 cytokines.

Authors:  Eun Sook Hwang; Ian Alexander White; I-Cheng Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

2.  Short-term culture of spleen lymphocytes for chromosome analysis of small rodents.

Authors:  M Jotterand Bellomo; D Mühlematter; M Nabholz
Journal:  Genetica       Date:  1990       Impact factor: 1.082

3.  Novel role of regulatory T cells in limiting early neutrophil responses in skin.

Authors:  Hannah Richards; Anwen Williams; Emma Jones; James Hindley; Andrew Godkin; Anna Katharina Simon; Awen Gallimore
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

4.  Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.

Authors:  Zulmarie Perez Horta; Swetha Saseedhar; Alexander L Rakhmilevich; Lakeesha Carmichael; Jacquelyn A Hank; Margaret Boyden; Stephen D Gillies; Paul M Sondel
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

5.  The role of CD4 T cells in the pathogenesis of murine AIDS.

Authors:  Wen Li; William R Green
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.

Authors:  H D Volk; O Josimovic-Alasevic; M Gross; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

7.  Requirements for activation of CD8+ murine T cells. I. Development of cytolytic activity.

Authors:  D C Cronin; D W Lancki; F W Fitch
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

8.  Unresponsiveness to Con A in spleen cell cultures of M. lepraemurium-infected mice is dependent on a defective expression of high-affinity IL-2 receptors rather than on a lack of IL-2 production.

Authors:  R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

9.  Dynamics of the intracerebral and splenic cytokine mRNA production in Toxoplasma gondii-resistant and -susceptible congenic strains of mice.

Authors:  M Deckert-Schlüter; S Albrecht; H Hof; O D Wiestler; D Schlüter
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

10.  Altered antigen receptor signaling in anergic T cells from self-tolerant T-cell receptor beta-chain transgenic mice.

Authors:  M A Blackman; T H Finkel; J Kappler; J Cambier; P Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.